Alejandra Monserrat Rodríguez-Ramírez

Dr. Alejandra Monserrat Rodríguez-Ramírez

CAIPaDi, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2021 in Complex Psychiatry
Verified
Journal Article
Open access
PDF file
BCBeatriz Camarena
Beatriz Camarena
EAElizabeth G. Atkinson
Elizabeth G. Atkinson
MBMark Baker
Mark Baker
CBClaudia Becerra-Palars
Claudia Becerra-Palars
LCLori B. Chibnik
Lori B. Chibnik
KKKarestan C. Koenen
Karestan C. Koenen
No large-scale genome-wide association studies (GWASs) of psychosis have been conducted in Mexico or Latin America to date. Schizophrenia and bipolar disorder in particular have been found to be highly heritable and genetically influenced. However, understanding of the biological basis of psychosis in Latin American populations is limited as previous genomic studies have almost exclusively relied on participants of Northern European ancestry. With the goal of expanding knowledge on the genomic basis of psychotic disorders within the Mexican population, the National Institute of Psychiatry Ramón de la Fuente Muñiz (INPRFM), the Harvard T.H. Chan School of Public Health, and the Broad Institute’s Stanley Center for Psychiatric Research launched the Neuropsychiatric Genetics Research of Psychosis in Mexican Populations (NeuroMex) project to collect and analyze case-control psychosis samples from 5 states across Mexico. This article describes the planned sample collection and GWAS protocol for the NeuroMex study. The 4-year study will span from April 2018 to 2022 and aims to recruit 9,208 participants: 4,604 cases and 4,604 controls. Study sites across Mexico were selected to ensure collected samples capture the genomic diversity within the Mexican population. Blood samples and phenotypic data will be collected during the participant interview process and will contribute to the development of a local biobank in Mexico. DNA extraction will be done locally and genetic analysis will take place at the Broad Institute in Cambridge, MA. We will collect extensive phenotypic information using several clinical scales. All study materials including phenotypic instruments utilized are openly available in Spanish and English. The described study represents a long-term collaboration of a number of institutions from across Mexico and the Boston area, including clinical psychiatrists, clinical researchers, computational biologists, and managers at the 3 collaborating institutions. The development of relevant data management, quality assurance, and analysis plans are the primary considerations in this protocol article. Extensive management and analysis processes were developed for both the phenotypic and genetic data collected. Capacity building, partnerships, and training between and among the collaborating institutions are intrinsic components to this study and its long-term success.

1 January 2023 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
ARAlejandra Monserrat Rodríguez-Ramírez
Alejandra Monserrat Rodríguez-Ramírez
MAMaría Teresa Alcántara-Garcés
María Teresa Alcántara-Garcés
SHSergio Hernandez
Sergio Hernandez
AUAna Cristina García Ulloa
Ana Cristina García Ulloa
DADenise Arcila-Martínez
Denise Arcila-Martínez
RARodrigo Eduardo Arizmendi-Rodríguez
Rodrigo Eduardo Arizmendi-Rodríguez
Introduction: Anxiety disorders (AXD) are among the most prevalent mental health conditions in patients with type 2 diabetes (T2D). Previous data have established an association of other psychiatric conditions with poor metabolic control and increased odds of diabetes-related complications. Nonetheless, follow-up information about the effects of AXD on the metabolic control of patients with TD2 is still limited. Objective: Evaluate the effects of AXD on the metabolic parameters of patients with T2D over 12 months of follow-up in a multidisciplinary comprehensive care model. Methods: Prospective study of T2D subjects enrolled in a comprehensive care program with follow-up at 3 and 12 months of treatment. Patients were assessed using the Mini-International Neuropsychiatric Interview and the Hospital Anxiety and Depression Scale (HADS). We registered clinical and metabolic characteristics from each visit. Metabolic parameters over time were analyzed with a mixed model of repeated measures using AXD and time as interaction variables. Results: Our sample included 2703 patients at baseline, and 1161 (43%) subjects continued the follow-up at 12 months. The AXD group had more females, lower age, and fewer years of formal education compared with subjects without AXD at baseline, 3 and 12 months. Patients with AXD also reported higher mean fasting glucose at three months, and higher HbA1c at three and 12 months. Our MMRM for HbA1c reported significant differences over time in subjects with and without AXD. The differences in means between groups increased from 0.17% at three months to 0.31% at 12 months. The variables from the HADS anxiety score, sex, age, years of diagnosis, and insulin treatment were also associated with HbA1c parameters over time. Conclusion: Patients with AXD had the worst glycemic control at 3 and 12 months of follow-up. HbA1c differences in patients with AXD compared with non-AXD subjects increases over time in association with anxiety symptoms.

1 June 2022 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
MAMaría Teresa Alcántara-Garcés
María Teresa Alcántara-Garcés
ARAlejandra Monserrat Rodríguez-Ramírez
Alejandra Monserrat Rodríguez-Ramírez
AUAna Cristina García Ulloa
Ana Cristina García Ulloa
SHSergio Hernandez
Sergio Hernandez
Purpose: To describe the metabolic status and clinical characteristics associated with NPPD in patients with less than five years of T2D diagnosis and explore the role of age in the presentation of psychiatric comorbidities. Patients and Methods: This was a cross-sectional study of subjects who attended a comprehensive care program. Patients were assessed using the Mini-International Neuropsychiatric Interview, and clinical and metabolic characteristics were registered. Multivariate logistic regression analyses were conducted to identify risk and protective factors for psychiatric disorders. We performed an analysis to further explore age’s influence on our results. Results: We included 1953 patients, and 40.1% had any psychiatric disorder. Younger age, female sex, and personal psychiatric history were associated with NPPD. The use of insulin was reported as a protective factor for eating disorders. Body mass index was associated with any psychiatric disorders and eating disorders. The analysis of age reported that patients younger than 45 years had the worst metabolic parameters and increased odds for NPPD, while patients older than 65 years had the best metabolic measures and decreased odds for psychiatric comorbidity. Conclusion: NPPD were frequent comorbidities in our sample; younger age, female sex, and personal psychiatric history were the most important factors associated with psychiatric comorbidities. Younger subjects experience a higher risk for psychiatric disorders and worst metabolic control.

3 November 2023 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Closed access
ARAlejandra Monserrat Rodríguez-Ramírez
Alejandra Monserrat Rodríguez-Ramírez
VCValente Cedillo‐Ríos
Valente Cedillo‐Ríos
MJMarco Antonio Sanabrais Jiménez
Marco Antonio Sanabrais Jiménez
CBClaudia Becerra‐Palars
Claudia Becerra‐Palars
SHSandra Hernández‐Muñoz
Sandra Hernández‐Muñoz
BCBeatriz Camarena
Beatriz Camarena

13 February 2024 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
MAMaría Teresa Alcántara-Garcés
María Teresa Alcántara-Garcés
ARAlejandra Monserrat Rodríguez-Ramírez
Alejandra Monserrat Rodríguez-Ramírez
AUAna Cristina García Ulloa
Ana Cristina García Ulloa
MAMARIO CESAR GARCIA ALANIS
MARIO CESAR GARCIA ALANIS
GMGabriela Nazareth Martínez-Reyes
Gabriela Nazareth Martínez-Reyes
PAPaloma Almeda-Valdés
Paloma Almeda-Valdés
Diabetes and poor glycemic control are significant predictors of severity and death in the COVID-19 disease. The perception of this risk in individuals with type 2 diabetes (T2D) could modify coping styles, leading to behaviors associated with better self-care and metabolic control. Theoretically, active coping is associated with better glycemic control in patients with T2D. Nonetheless, information during extreme risk like the COVID-19 pandemic is still limited. Our objective was to evaluate the association between coping styles and risk perception in the COVID-19 pandemic and the change in metabolic parameters. This is a prospective study that included individuals with T2D treated in a tertiary care center during the COVID-19 outbreak who returned to follow-up one year later. We assessed coping styles and risk perception with the Extreme Risk Coping Scale and the risk perception questionnaire. Clinical characteristics and metabolic parameters were registered in both visits. Groups were compared using Kruskal Wallis tests, and changes in metabolic parameters were assessed with Wilcoxon rank sum tests. Our sample included 177 participants at baseline, and 118 concluded the study. Passive coping was more frequent in women. Low-risk perception was associated with higher age, lower psychiatric comorbidities, and lower frequency of psychiatric treatment compared with other risk perception groups. Patients with active coping plus high-risk perception did not have a change in metabolic parameters at follow-up, whereas patients with other coping styles and lower risk perception had an increase in total cholesterol, LDL-cholesterol, and triglycerides. There were no differences by coping group or by risk perception in glycemic control.

27 February 2026 in Brain Sciences
Verified
Journal Article
Open access
PDF file
ARAlejandra Monserrat Rodríguez-Ramírez
Alejandra Monserrat Rodríguez-Ramírez
MBMariela Benitez-Valenzuela
Mariela Benitez-Valenzuela
MAMaría Teresa Alcántara-Garcés
María Teresa Alcántara-Garcés
MJMarco Antonio Sanabrais Jiménez
Marco Antonio Sanabrais Jiménez
JHJulio Uriel Zaragoza Hoyos
Julio Uriel Zaragoza Hoyos
BCBeatriz Camarena-Medellin
Beatriz Camarena-Medellin
Introduction: Major depressive disorder (MDD) is a common comorbidity of type 2 diabetes (T2D) with low rates of treatment response to antidepressants. The pathophysiology of these conditions overlaps in N-methyl-d-aspartate receptors (NMDARs), which are present in neurons and pancreatic cells. GRIN1 encodes NMDARs and has been associated with depression and T2D; however, its role in the coexistence of MDD and T2D and the treatment response to antidepressants has yet to be explored. Objective: We aimed to evaluate the association between GRIN1 rs28489906 and MDD and treatment response to antidepressants in patients with T2D. Methods: A prospective study was conducted on T2D patients enrolled in a comprehensive care program with follow-up at 3 months. Subjects were assessed for MDD, and genotyping for GRIN1 rs28489906 was performed. Depression scores and glycated hemoglobin (HbA1c) were analyzed using the Wilcoxon paired signed-rank test, and a stratified analysis was conducted to assess treatment response. Logistic regression analyses were performed to predict MDD and treatment response. Results: Our sample included 232 patients; among them, 49 (21%) had MDD. Patients with MDD showed a higher frequency of the AA genotype compared with non-MDD subjects (p = 0.026). A allele carriers reported lower treatment response rates (p = 0.049) and decreased odds of treatment response (OR = 0.03, 95% CI 0.002–0.63, p = 0.023). Patients with AG and AA genotypes with treatment response exhibited lower HbA1c (p = 0.029). Conclusions: The A allele of GRIN1 rs28489906 was associated with MDD and treatment response in patients with T2D. Our findings highlight the role of glutamate in these comorbidities and the need for different therapeutic approaches based on genetics.